SPRAVATO® is a prescription medicine, used along with an antidepressant taken by mouth to treat:
- Adults with treatment-resistant depression (TRD)
- Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions
SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.
It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.
It is not known if SPRAVATO® is safe and effective in children.
What are common side effects of taking SPRAVATO?
- Spinning sensation
- Reduced sense of touch and sensation
- Lack of energy
- Increased blood pressure
- Feeling drunk
What should I do if I miss a treatment session?
It is important to stay on track with your treatment plan. However, if you do miss any treatments, contact your healthcare
provider as soon as possible to discuss how they would like to address the situation. They may decide to change your dose,
or dosing frequency, because of missed treatments.
How long will I stay on SPRAVATO for treatment-resistant depression?
You and your healthcare provider will decide how long to stay on SPRAVATO based on how you respond to it. Your
healthcare provider will determine the dosing frequency based on how you feel.
How often will I take SPRAVATO for treatment-resistant depression?
You’ll take SPRAVATO twice a week for the first month. During the second month, you’ll take it once a week. After that, you
will take it once a week or once every two weeks. You’ll continue to take your oral antidepressant as prescribed.
How quickly might I see improvement of depressive symptoms with SPRAVATO for treatment-resistant depression?
In clinical studies, improvement of depressive symptoms was demonstrated at four weeks by SPRAVATO plus an oral
antidepressant, compared with placebo nasal spray plus an oral antidepressant. Not all patients will respond to SPRAVATO.